Clinical trials for Pancreas cancer

154 currently recruiting clinical trials
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06589596 #2024-515307-19-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
BeOne Medecines
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06619587
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Genentech, Inc
Phase 1 Breast cancer Lung cancer Pancreas cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Cervical / Vulvar / Vaginal cancer #NCT04389632
Parties A et B (escalade de dose)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Invasive bladder cancer Epithelial ovarian cancer
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC Adenocarcinoma Squamous cell carcinoma Urothelial carcinoma Serous high grade carcinoma (HGSOC) Other
Required HER2 statuses
HER2 Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Seagen
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06220864 #2025-520557-36-00
Escalade et extension de dose monothérapie et escalade de dose combinaison
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Synnovation Therapeutics, Inc.
Phase 1 Lung cancer Colon cancer Rectal cancer Pancreas cancer Stomach and esophageal cancer #NCT06131840
Partie A et B
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
1 recruiting site
Seagen
Phase 1 Pancreas cancer #NCT06131840
Partie E Adénocarcinome canalaire pancréatique
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
1 recruiting site
Seagen
Phase 1 Breast cancer Lung cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Head and neck cancer #NCT05208762 #2023-506604-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Esophagus Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC Adenocarcinoma Hepatocellular carcinoma Squamous cell carcinoma
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20) CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Seagen
Phase 1 Colon cancer Rectal cancer Pancreas cancer #NCT07094113
Partie 3b: Exploration et expansion des doses en thérapie combinée CCR et PDAC
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS KRAS G12C KRAS non G12C KRAS G12D
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Amgen
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06561685
Phase 1a Escalade de dose
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
SMARCA4
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Eli Lilly et compagnie
Phase 1 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06561685
Phase 1b Extension Partie B
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
SMARCA4
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Eli Lilly et compagnie